Premium
Deprenyl (selegiline) in combination treatment of Parkinson's disease
Author(s) -
GERSTENBRAND F.,
RANSMAYR G.,
POEWE W.
Publication year - 1983
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1983.tb01526.x
Subject(s) - selegiline , levodopa , decarboxylase inhibitor , dyskinesia , parkinson's disease , medicine , pharmacology , anesthesia , disease
— Long‐term treatment of parkinsonian patients with levodopa (plus decarboxylase inhibitor) leads to decreasing levodopa efficacy and increasing side‐effects. Then main therapeutic problems are on‐off phenomena, end‐of‐dose akinesia and levodopa‐induced dyskinesias. Deprenyl, a selective MAO‐B inhibitor, has produced good therapeutic effects in combination either with levodopa alone or with levodopa plus decarboxylase inhibitor in the treatment of end‐of‐dose akinesia and on‐off phenomena. In an open trial with 48 parkinsonian patients deprenyl was added to previous levodopa plus decarboxylase‐inhibitor therapy. Good effects were achieved in respect of mild on‐off phenomena and end‐of‐dose akinesia, minor success in the alleviation of dyskinesia and depression. In four further patients with a post‐traumatic parkinsonian syndrome, no improvement of rigidospasticity and vigilance was demonstrable.